ArticleChronic respiratory disease2016
Annual direct medical costs of bronchiectasis treatment: Impact of severity, exacerbations, chronic bronchial colonization and chronic obstructive pulmonary disease coexistence.
Article in Chronic respiratory disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 6 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Coexistence of COPD or asthma in patients with bronchiectasis: a systematic review and meta-analysis.BMC pulmonary medicine · 2026Pooled it
- Inhaled tobramycin for chronic pseudomonas aeruginosa infection in non-cystic fibrosis bronchiectasis: an updated systematic review and meta-analysis.BMC pulmonary medicine · 2026Pooled it
- A systematic literature review of the clinical and socioeconomic burden of bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Pooled it
- Intermittent prophylactic antibiotics for bronchiectasis.The Cochrane database of systematic reviews · 2022Pooled it
- The economic burden of bronchiectasis - known and unknown: a systematic review.BMC pulmonary medicine · 2019Pooled it
- Continuous versus intermittent antibiotics for bronchiectasis.The Cochrane database of systematic reviews · 2018Pooled it
- Epidemiology of bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Economic Burden of Chronic Obstructive Pulmonary Disease: A Systematic Review.Tuberculosis and respiratory diseases · 2024Article
- Use of infection control measures in people with chronic lung disease: mixed methods study.ERJ open research · 2024Article
- Hemoptysis as the presenting manifestation of bronchiectasis-associated hospitalization in Korea.Journal of thoracic disease · 2023Article
- Healthcare costs and resource utilisation in bronchiectasis, asthma and COPD.ERJ open research · 2023Article
- The relation between inspiratory muscle strength and bacterial colonization and other clinical factors in patients with non-cystic fibrosis bronchiectasis.Tuberkuloz ve toraks · 2023Article
- Effects of Probiotics on Clinical Manifestations of Bronchiectasis: A Randomized, Triple Blinded, Placebo-Controlled Clinical Trial.Tanaffos · 2023Article
- Impact of the SARS-CoV-2 Virus Pandemic on Patients with Bronchiectasis: A Multicenter Study.Antibiotics (Basel, Switzerland) · 2022Article
- Inhaled Colistimethate Sodium in the Management of Patients with Bronchiectasis Infected byInfection and drug resistance · 2022Review
- Telemedicine and Remote Monitoring as an Adjunct to Medical Management of Bronchiectasis.Life (Basel, Switzerland) · 2021Review
- Prevalence of asymptomatic bronchiectasis and associations among the health screening population in South Korea.ERJ open research · 2021Article
- Correlation between clinical-functional parameters and number of lobes involved in non-cystic fibrosis bronchiectasis.Multidisciplinary respiratory medicine · 2021Article
- Impact ofJournal of clinical medicine · 2020Review
- Clinical features related to hospital expenses for non-cystic fibrosis bronchiectasis in China.The Journal of international medical research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with bronchiectasis (BE) present exacerbations that increase with severity of the disease. We aimed to determine the annual cost of BE treatment according to its severity, determined by FACED score, as well as the parameters associated with higher costs. Multicentre historical cohorts study with patients from six hospitals in Spain. The costs arising during the course of a year from maintenance treatment, exacerbations, emergency visits and hospital admissions were analysed. In total, 456 patients were included (56.4% mild BE, 26.8% moderate BE and 16.9% severe BE). The mean cost was €4671.9 per patient, which increased significantly with severity. In mild BE, most of the costs were due to bronchodilators and inhaled steroids; in severe BE, most were due to exacerbations and inhaled antibiotics. Forced expiratory volume in 1 second (FEV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.